4,552 publications from this institution
No abstract is provided for this article.
Interferon could be recovered from homologous cells to which it was applied but could not be recovered from heterologous cells. The amount of interferon that could be recovered from cells corresponded to the sensitivity of the cells to the antiviral activity of the interferon: mouse embryo fibroblasts, which were 5 to 10 times as sensitive as L-929 cells to interferon, bound 5 to 10 times more interferon than the latter, whereas Lpa cells, which were only one-third as sensitive as L-929 cells to interferon, bound only one-third as much as the latter. The concentration of cell-bound interferon was as much as 150 times the extracellular concentration of interferon applied to the cells. Interferon bound to cells at 4 C with the same efficiency as it did to cells at 37 C, and actinomycin D-treated cells bound interferon as well as normal cells. Even though the total amount of interferon bound to cells was as much as 30% of the amount of interferon applied to them, no loss of antiviral activity was detectable from the medium.
Several nucleoside and nucleotide analogues have been identified as potent antiviral agents with convincing activity against poxviruses (including variola, vaccinia, monkeypox, cowpox, molluscum contagiosum, orf). Among the nucleoside analogues, 8-methyladenosine and 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242), have been identified as promising anti-poxvirus agents. Among the nucleotide analogues, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC, cidofovir], (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine [(S)-HPMPDAP] and (S)-6-(3-hydroxy-2-phosphonylmethoxypropyl)oxy-2,4-diaminopyrimidine [(S)-HPMPO-DAPy] have been identified as promising anti-poxvirus agents. These nucleoside and nucleotide analogues have proved to be efficacious in various animal models for poxvirus infections. Only one compound, cidofovir, has also proved efficacious against poxvirus infections in humans, i.e. molluscum contagiosum and orf (sheep pox). Cidofovir is formally licensed for clinical use (intravenous administration for the treatment of cytomegalovirus retinitis in AIDS patients); however, it could also be formulated for topical administration, or for oral administration in prodrug form, i.e. as 1-O-hexadecyloxypropyl-cidofovir.
Human cytomegalovirus (HCMV) infections are a major cause of mortality and morbidity in human transplant recipients and a serious problem in patients with AIDS. Furthermore, CMV is the most frequent viral cause of congenital abnormalities. Two drugs are currently licensed for the treatment of severe CMV infections, i.e. ganciclovir (Cymevene) and foscarnet (Foscavir). However, both compounds may give severe side-effects, and resistant strains may emerge during long-term therapy. Therefore, the development of new and more effective anti-CMV drugs is one of the top priorities in current antiviral drug research. The first goal of our study was to devise an assay for the rapid and automated screening of large series of compounds against CMV. The new method that we present is based on the enhanced esterase activity in the CMV-infected cell. The method significantly reduces labor time as compared to the microscopical method that is currently used. Secondly, we investigated the anti-CMV activity of the acyclic nucleoside phosphonate (ANP) analogue HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. HPMPC was recently identified in our laboratory as the most potent and selective anti-CMV compound described so far. We found that HPMPC specifically inhibits viral DNA synthesis and that the compound is endowed with an unique long-lasting antiviral effect. We then compared the antiviral potencies of HPMPC and ganciclovir in murine models for murine CMV (MCMV) infections. As could be expected from our in vitro data, HPMPC was far superior over ganciclovir in preventing MCMV-induced mortality. In order to mimic more closely the HCMV disease progression in immunocompromised patients, we elaborated a model for MCMV infections in mice with severe combined immune deficiency (SCID). The anti-CMV activity of HPMPC and DHPS was compared in several clinical relevant treatment schedules in the SCIO mouse model. HPMPC appeared in all conditions to be much more effective than ganciclovir. We also found that PMEDAP [9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine], an ANP with potent antiretroviral activity, is highly efficacious in the treatment of MCMV-associated mortality in both immunocompetent and immunodeficient (SCID) mice. Our third aim was to determine the mechanism by which polyanionic polymers [sulfated polymers, polycarboxylates and polyoxometalates] exhibit anti-HCMV activity. All these compounds were found to inhibit the adsorption of HCMV to the cells.(ABSTRACT TRUNCATED AT 400 WORDS)
Human fibroblast interferon (HFIF) and human leukocyte interferon (HLIF) can protect mouse L-929 cells against the cytopathic effects of vesicular stomatitis virus (VSV), although HLIF is about 60 times and HFIF about 1200 times less active than mouse interferon (MIF). This relationship suggests that, with repsect to the mouse L-929 receptor, there exists a greater similarity between the active sites of MIF and HLIF than between MIF and HFIF. Employing antibodies directed against MIF, HFIF, and HLIF as a probe, we found interferon-cell interactions to be stronger for homologous than for heterologous combinations. A variable-fit model is proposed to explain the differences that interferons display in cross-species protection. Thus, the closer the fit between interferon and receptor, the greater the antiviral response.